TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sosei Group ( (JP:4565) ) just unveiled an update.
Nxera Pharma has launched a new pipeline targeting obesity and chronic weight management, led by a proprietary oral GLP-1 agonist and six additional programs targeting GIP, Amylin, and Apelin receptors. This initiative aims to transform the treatment landscape for obesity and associated metabolic disorders, addressing long-term weight management and co-morbid conditions. The pipeline leverages Nxera’s NxWave™ platform to develop highly differentiated drug candidates, positioning the company as a leader in next-generation obesity therapies. The announcement follows Pfizer’s discontinuation of a related GLP-1 agonist, with Nxera planning discussions for potential opportunities with Pfizer.
The most recent analyst rating on (JP:4565) stock is a Buy with a Yen2000.00 price target. To see the full list of analyst forecasts on Sosei Group stock, see the JP:4565 Stock Forecast page.
More about Sosei Group
Nxera Pharma is a technology-powered biopharmaceutical company focused on developing specialty medicines to address unmet medical needs in Japan and globally. The company operates an agile commercial business in Japan and the broader APAC region, leveraging its NxWave™ discovery platform to advance a pipeline of over 30 active programs in areas such as obesity, metabolic disorders, neurology, and immunology. Nxera employs approximately 400 people across locations in Japan, the UK, Switzerland, and South Korea, and is listed on the Tokyo Stock Exchange.
Average Trading Volume: 736,770
Technical Sentiment Signal: Sell
Current Market Cap: Yen83.53B
Learn more about 4565 stock on TipRanks’ Stock Analysis page.